Avadel Pharmaceuticals plc (NASDAQ:AVDL) saw an upside of 5.05% to $7.70 after adding $0.37 on Wednesday. The 5-day average trading volume is 496,991 shares of the company’s common stock. It has gained $7.82 in the past week and touched a new high 5 times within the past 5 days. An average of 409,108 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 671,529.
AVDL’s 1-month performance is 7.79% or $0.76 on its low of $6.29 reached on 12/28/22. The company’s shares have touched a 52-week low of $1.05 and high of $10.02, with the stock’s rally to the 52-week high happening on 01/25/23. YTD, AVDL has achieved 2.37% or $0.58 and has reached a new high 4 times. However, the current price is down -23.15% from the 52-week high price.
AVDL stock has a beta of 1.61.
Avadel Pharmaceuticals plc’s quick ratio for the period ended September 29 was 2.70, with the current ratio over the same period at 2.70.
For the quarterly period ending September 29 this year, Avadel Pharmaceuticals plc’s cash and short-term investments amounted to $45.76 million against total debt of $138.27 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -9.18% to -$20.15 million, while revenue of -$63.44 million was -214.84% off the previous quarter. Analysts expected AVDL to announce -$0.25 per share in earnings in its latest quarter, but it posted -$0.33, representing a -32.00% surprise. EBITDA for the quarter stood at more than -$16.56 million. AVDL stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 158.2 million, with total debt at $138.27 million. Shareholders hold equity totaling $61.78 million.
Let’s look briefly at Avadel Pharmaceuticals plc (AVDL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 66.40% to suggest the stock is trending Neutral, with historical volatility in this time period at 65.14%.
The stock’s 5-day moving average is $7.08, reflecting a +14.50% or $0.98 change from its current price. AVDL is currently trading +10.89% above its 20-day SMA, +16.57% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +24.84% and SMA200 by+16.22%.
Stochastic %K and %D was 70.95% and 51.71% and the average true range (ATR) pointed at 0.44. The RSI (14) points at 59.12%, while the 14-day stochastic is at 94.59% with the period’s ATR at 0.47. The stock’s 9-day MACD Oscillator is pointing at 0.35 and 0.34 on the 14-day charts.
In the most recent analyst report for Avadel Pharmaceuticals plc (NASDAQ: AVDL), Jefferies upgraded it to a Buy rating. They previously had a Hold rating on the stock. Analysts offering their rating for AVDL stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate AVDL as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.
What is AVDL’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $7.00 and a high of $19.00, with their median price target at $12.00. Looking at these predictions, the average price target given by analysts is for Avadel Pharmaceuticals plc (AVDL) stock is $12.55.